“Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study”, J of Skin, vol. 7, no. 2, p. s114, Mar. 2023, doi: 10.25251/skin.7.supp.114.